📰 Nasdaq Coll News
Page 5 - Nasdaq Coll News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Coll. Real-time updates on events, politics, business and more.
May 2, 2023
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) is set to release its earnings data after the market closes on Thursday, May 4th. Analysts expect Collegium Pharmaceutical to post earnings of $1.26 per share for the quarter. Collegium Pharmaceutical has set its FY 2023 guidance at EPS.Persons interested in listening to the company’s earnings conference call can […]
May 1, 2023
South Dakota Investment Council grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 281,572 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,725 shares during […]
April 28, 2023
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) had its price target lowered by Piper Sandler from $37.00 to $35.00 in a research report released on Tuesday, The Fly reports. Other research analysts also recently issued research reports about the stock. StockNews.com began coverage on shares of Collegium Pharmaceutical in a research report on Thursday, March 16th. […]
April 25, 2023
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) had its price objective cut by equities researchers at Piper Sandler from $37.00 to $35.00 in a research note issued to investors on Tuesday, The Fly reports. Piper Sandler’s price objective suggests a potential upside of 49.57% from the stock’s current price. A number of other equities research analysts […]
April 25, 2023
Mesirow Institutional Investment Management Inc. reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 23.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 290,534 shares of the specialty pharmaceutical company’s stock after selling 89,831 shares during the period. Mesirow […]
April 22, 2023
Emerald Mutual Fund Advisers Trust cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 685,893 shares of the specialty pharmaceutical company’s stock after selling 9,500 shares during the period. […]
April 9, 2023
MetLife Investment Management LLC cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,661 shares of the specialty pharmaceutical company’s stock after selling 2,676 shares during the period. MetLife Investment Management LLC owned […]
June 2, 2022
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) has been given a consensus rating of “Buy” by the seven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The […]
May 22, 2022
Wall Street brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) to report earnings per share (EPS) of $1.42 for the current quarter, according to Zacks. Five analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $1.25 to $1.75. Collegium Pharmaceutical reported earnings of $0.27 per share during the same quarter last […]
May 8, 2022
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) has been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the […]